BTAI stock · JLL stock

BTAI vs JLL · rev $388.0K vs P/E 23, rev $13.31B

BioXcel Therapeutics Inc (BTAI) versus Jones Lang LaSalle Incorporated (JLL) — a side-by-side from cached financials, not a winner call.

BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.

Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.

Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.

Latest reported JLL revenue for 2026-06-30 was $13.31B. Net income was $373.7M. JLL currently screens at market cap $12.12B and trailing P/E 23.0.

BTAI currently screens at market cap $36.1M. JLL currently screens at market cap $12.12B and trailing P/E 23.0.

Not investment advice. Open the BTAI and JLL stock pages for the full models.

Not investment advice.

Popular Stock Comparisons